A subgroup analysis of the SAVANT trial found that nabiximols (THC:CBD spray) halved spasticity and pain severity scores across all patient subgroups, with severe spasticity patients showing the largest benefits.
Neurologists, MS specialists, and patients with resistant MS spasticity.
Nabiximols halved spasticity scores across all disability subgroups
What the researchers found
In post hoc analysis of the SAVANT RCT, THC:CBD oromucosal spray halved mean spasticity and pain severity scores across all subgroups defined by disability level (EDSS), spasticity severity, and spasticity duration. Active treatment significantly improved spasticity from week 4 onward. Patients with severe resistant spasticity achieved the most significant therapeutic gains.
Why it matters
Clinicians need to know which MS patients benefit most from nabiximols. This analysis shows consistent benefit across disability levels and durations, with the strongest signals in the most severely affected patients.
The numbers in context
THC:CBD spray halved mean spasticity and pain NRS scores in all subgroups; significant improvement from week 4 in both EDSS subgroups, severe spasticity subgroup, and both duration subgroups.
How the study worked
Post hoc subgroup analysis of the SAVANT randomized, double-blind, placebo-controlled trial of nabiximols vs. optimized first-line antispastics in resistant MS spasticity, stratified by EDSS score, spasticity severity, and spasticity duration.
What this study cannot tell us
Post hoc subgroup analysis (not pre-specified); single RCT dataset; subgroups may be underpowered for some comparisons; 12-week treatment period.
How to read the evidence
Strong: based on a well-designed RCT, though this is a post hoc subgroup analysis.
When this study was published
Published 2020.
The bigger picture
The consistency of benefit across subgroups strengthens the evidence for nabiximols in MS spasticity. Unlike many treatments that work mainly in mild cases, this one appears most effective in severe disease.
Questions still open
- Does the benefit persist beyond 12 weeks? Would earlier initiation of nabiximols prevent progression to severe spasticity?
Common questions
Does nabiximols work for all levels of MS spasticity?
How quickly does nabiximols start working?
Read the original research
Tetrahydrocannabinol and cannabidiol oromucosal spray in resistant multiple sclerosis spasticity: consistency of response across subgroups from the SAVANT randomized clinical trial.
The International journal of neuroscience, 130(12), 1199-1205
Citation
Meuth, Sven G; Henze, Thomas; Essner, Ute; Trompke, Christiane; Vila Silván, Carlos. (2020). Tetrahydrocannabinol and cannabidiol oromucosal spray in resistant multiple sclerosis spasticity: consistency of response across subgroups from the SAVANT randomized clinical trial.. The International journal of neuroscience, 130(12), 1199-1205. https://doi.org/10.1080/00207454.2020.1730832
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk